Weight & Metabolism · commonly explored around metabolism and appetite
GLP3
Retatrutide, shown here as GLP3, targets three appetite and metabolism signals at once. In a phase 2 trial, people lost about 24% of their body weight on average over 48 weeks, and it is now in late-stage trials.
Informational profile
No verified OnimaChain inventory for this profile.
Compound: retatrutide
Also known as LY3437943 · GLP3 (display name)
- Sequence
- YXQGTFTSDYSIXLDKKAQXAFIEYLLEGGPSSGAPPPS
- Length
- 39 residues
- MW
- —
- Product tags
- glp 1r · gip r · glucagon r
- Checked sources
- No checked source added yet
- Structure provenance
- Rendered from deposited C-alpha coordinates · RCSB PDB 8YW5 chain P; any unresolved tail is modeled
Displayed as GLP3. Compound: retatrutide. The sequence includes Aib at residues 2 and 20, α-methyl-leucine at 13, a lipid tether at Lys17 and a C-terminal amide.
See the simple guide ↓Video intro
GLP3 in ten seconds.
Coming soon.
Meet GLP3
The short version, before the deep dive.
Retatrutide, shown here as GLP3, targets three appetite and metabolism signals at once. In a phase 2 trial, people lost about 24% of their body weight on average over 48 weeks, and it is now in late-stage trials.
PulseChain
What’s new with GLP3
Section B
The quick read
Section C
Research at a glance
A simple picture of the sources we have checked. More color means more records in that category—not that the product works better.
We haven’t added a checked source for this yet.
This picture fills in as we add checked studies for this product.
Section D
What the sources looked at
These topics come only from sources in our record. We do not add a topic just because it is popular online.
No topics yet
Topics show up here once we have checked studies for this product and sorted them.
Section E
Why people look it up
A plain-language starting point. This is not a promise that the product will cause a result.
metabolism and appetite
See GLP3 beside similar names.
The Portal of Tides lets you switch between a constellation, connection view, checked-source timeline, and topic map. It uses the products already in our collection—no fake customer counts.
Section F
What the record can tell us
A product page can show what was studied. It cannot promise what will happen to a person.
What we can show
No source topic has been added yet.
What we cannot promise
A lab result, animal study, online story, or product page cannot tell you what will happen to you. That question needs qualified medical guidance.
Section G
Claims people make
The big claims tied to this product. Open one to see where it came from and how it spread.
No claims tracked for this product yet
We only add a claim once we can point to where it started, or say clearly that we could not find out.
Section H
How far it has been tested
From cells in a dish, to mice, rats, bigger animals, people, proper trials, and finally regulator approval. The light stops where the checked studies stop.
We have not mapped how far any result has been tested yet.
Section I
How many separate teams
Ten papers from one lab are not ten separate confirmations.
Not checked yet
We only count teams from studies we have confirmed.
Section J
What doesn’t fit?
If a study disagrees, it goes here. We do not hide it.
No study we have checked pushes back yet
Studies that found nothing, disagree, or criticize the method will show up here once we add them. A study that only partly agrees is not the same as one that disagrees.
Section K
Timeline
What happened and when. Studies in one lane, real-world reports in another.
Research
0 events
No dated research update is indexed for this selection.
Trials
0 events
No trial milestones are indexed to this exact record yet.
Regulatory
0 events
No regulator decisions listed yet.
Real-world reports
0 events
No real-world reports yet — social platforms are not connected.
Section L
Sources
Every study we used. Only studies we confirmed on PubMed are shown as sources. Where a drug is FDA-approved, its official label sits beside them — that is an approval, not a sales pitch.
No official FDA label for this product
We only attach an FDA record when the molecule is an approved drug and we have checked the application number. Most research peptides will stay empty here.
We haven’t added a checked source for this yet.
The building blocks, one by one
| # | Code | Residue | Class | Chirality | Features |
|---|---|---|---|---|---|
| 1 | Y | Tyrosine | polar | L | |
| 2 | Aib | α-Aminoisobutyric acid | hydrophobic | L | Aib |
| 3 | Q | Glutamine | polar | L | |
| 4 | G | Glycine | special | L | flexible |
| 5 | T | Threonine | polar | L | |
| 6 | F | Phenylalanine | hydrophobic | L | |
| 7 | T | Threonine | polar | L | |
| 8 | S | Serine | polar | L | |
| 9 | D | Aspartate | negative | L | |
| 10 | Y | Tyrosine | polar | L | |
| 11 | S | Serine | polar | L | |
| 12 | I | Isoleucine | hydrophobic | L | |
| 13 | MeLeu | α-Methyl-leucine | hydrophobic | L | Non-standard residue |
| 14 | L | Leucine | hydrophobic | L | |
| 15 | D | Aspartate | negative | L | |
| 16 | K | Lysine | positive | L | |
| 17 | K | Lysine | positive | L | Acyl tether |
| 18 | A | Alanine | hydrophobic | L | |
| 19 | Q | Glutamine | polar | L | |
| 20 | Aib | α-Aminoisobutyric acid | hydrophobic | L | Aib |
| 21 | A | Alanine | hydrophobic | L | |
| 22 | F | Phenylalanine | hydrophobic | L | |
| 23 | I | Isoleucine | hydrophobic | L | |
| 24 | E | Glutamate | negative | L | |
| 25 | Y | Tyrosine | polar | L | |
| 26 | L | Leucine | hydrophobic | L | |
| 27 | L | Leucine | hydrophobic | L | |
| 28 | E | Glutamate | negative | L | |
| 29 | G | Glycine | special | L | flexible |
| 30 | G | Glycine | special | L | flexible |
| 31 | P | Proline | special | L | Proline kink |
| 32 | S | Serine | polar | L | |
| 33 | S | Serine | polar | L | |
| 34 | G | Glycine | special | L | flexible |
| 35 | A | Alanine | hydrophobic | L | |
| 36 | P | Proline | special | L | Proline kink |
| 37 | P | Proline | special | L | Proline kink |
| 38 | P | Proline | special | L | Proline kink |
| 39 | S | Serine | polar | L | C-terminal amide |